FibroGen Inc. Files 8-K
Ticker: KYNB · Form: 8-K · Filed: Mar 31, 2025 · CIK: 921299
| Field | Detail |
|---|---|
| Company | Fibrogen Inc (KYNB) |
| Form Type | 8-K |
| Filed Date | Mar 31, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, disclosure
TL;DR
FibroGen filed an 8-K on March 31st for an event on March 28th. Details pending.
AI Summary
FibroGen, Inc. filed an 8-K on March 31, 2025, reporting an event that occurred on March 28, 2025. The filing is categorized under Regulation FD Disclosure. No specific financial transactions or material events are detailed in the provided excerpt.
Why It Matters
This filing indicates FibroGen, Inc. is making a disclosure to the SEC, which could contain important information for investors regarding company events or communications.
Risk Assessment
Risk Level: low — The provided excerpt is a standard SEC filing header and does not contain specific financial or operational details that would indicate a high-risk event.
Key Players & Entities
- FibroGen, Inc. (company) — Registrant
- March 28, 2025 (date) — Date of earliest event reported
- March 31, 2025 (date) — Date of report
- 350 Bay Street Suite 100 #6009 (address) — Principal Executive Offices
- San Francisco, California (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to serve as a Regulation FD Disclosure, reporting an event that occurred on March 28, 2025.
When was this 8-K report filed with the SEC?
This 8-K report was filed with the SEC on March 31, 2025.
What is the exact name of the company filing this report?
The exact name of the company filing this report is FibroGen, Inc.
What is the principal executive office address for FibroGen, Inc.?
The principal executive office address for FibroGen, Inc. is 350 Bay Street Suite 100 #6009, San Francisco, California.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 31, 2025 regarding FIBROGEN INC (KYNB).